HOROWITZ BENJAMIN A — SEC Form 4 filings
SEC reporting owner CIK 1166586. 26 Form 4 filings on record with FilingPulse; latest filed 2026-08-24.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2024-06-13 to 2026-08-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 16 legs across 7 filings — 4,932,846 shares, $75,653,960 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 46 legs across 7 filings — 7,205,690 shares, $96,906,566 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 111.
- Largest priced transaction: purchase of 1,100,000 shares @ $18.00 ($19,800,000) in Braveheart Bio, Inc., filed 2026-08-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Samsara Inc. (IOT) | 10% owner | 10 | — | 44 legs · 2,205,690 sh · $85,156,566 | 70 |
| Navan, Inc. (NAVN) | Director, 10% owner | 8 | 12 legs · 2,772,241 sh · $42,853,973 | — | 19 |
| Braveheart Bio, Inc. (BRVE) | 10% owner | 1 | 1 leg · 1,100,000 sh · $19,800,000 | — | 2 |
| Nautilus Biotechnology, Inc. (NAUT) | 10% owner | 1 | — | 2 legs · 5,000,000 sh · $11,750,000 | — |
| Camp4 Therapeutics Corp (CAMP) | 10% owner | 1 | 2 legs · 727,272 sh · $7,999,992 | — | 3 |
| Scribe Therapeutics, Inc. (SCTX) | 10% owner | 1 | 1 leg · 333,333 sh · $4,999,995 | — | 4 |
| Starco Brands, Inc. (STCB) | 10% owner | 2 | — | — | 8 |
| Okta, Inc. (OKTA) | Director | 2 | — | — | 5 |
Form 4 filings — HOROWITZ BENJAMIN A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-24 | 4 | Navan, Inc. (NAVN) | Grant/award (A): 657 @ $28.56 | EDGAR |
| 2026-08-11 | 4 | Braveheart Bio, Inc. (BRVE) jointly with AH Bio Fund IV, L.P., AH Equity Partners Bio IV, L.L.C., Andreessen Marc L | Conversion (C): 9,132,420 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Scribe Therapeutics, Inc. (SCTX) jointly with AH Bio Fund II, L.P., AH Equity Partners Bio II, L.L.C., AH Bio Fund III, L.P., AH Equity Partners Bio III, L.L.C., Andreessen Marc L | Conversion (C): 2,051,742 · Conversion (C): 697,650 · Purchase (P): 333,333 @ $15 · Conversion (C): 12,150,003 (derivative) @ $0 · Conversion (C): 4,131,344 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Navan, Inc. (NAVN) | Grant/award (A): 9,959 @ $0 | EDGAR |
| 2026-06-04 | 4 | Nautilus Biotechnology, Inc. (NAUT) jointly with AH Equity Partners Bio II, L.L.C., Andreessen Horowitz LSV Fund II, L.P., AH Bio Fund II, L.P., AH Equity Partners LSV II, L.L.C., Andreessen Marc L | Sale (S): 4,615,974 @ $2.35 · Sale (S): 384,026 @ $2.35 | EDGAR |
| 2026-05-22 | 4 | Navan, Inc. (NAVN) | Grant/award (A): 1,012 @ $18.54 | EDGAR |
| 2026-01-09 | 4 | Navan, Inc. (NAVN) | Purchase (P): 46,337 @ $18.11 | EDGAR |
| 2026-01-06 | 4 | Navan, Inc. (NAVN) | Purchase (P): 466,058 @ $16.27 · Purchase (P): 202,729 @ $15.77 · Purchase (P): 308,188 @ $16.74 | EDGAR |
| 2025-12-29 | 4 | Navan, Inc. (NAVN) | Purchase (P): 334,112 @ $15.90 · Purchase (P): 225,484 @ $15.84 · Purchase (P): 167,519 @ $15.83 · Purchase (P): 229,917 @ $15.57 · Purchase (P): 99,502 @ $16.16 | EDGAR |
| 2025-12-19 | 4 | Navan, Inc. (NAVN) | Purchase (P): 347,600 @ $12.65 · Purchase (P): 103,960 @ $13.61 · Purchase (P): 240,835 @ $14.70 | EDGAR |
| 2025-11-04 | 4 | Navan, Inc. (NAVN) | Conversion (C): 6,757,090 · Conversion (C): 4,305,906 · Conversion (C): 607,161 · Conversion (C): 2,081,772 · Conversion (C): 17,001 · Conversion (C): 10,408,860 · +10 more | EDGAR |
| 2025-09-10 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Other (J): 1,255,907 @ $0 · Other (J): 10,949,014 @ $0 · Other (J): 994,899 @ $0 · Other (J): 2,573,745 @ $0 · Other (J): 33,331 @ $0 · Other (J): 868,485 @ $0 · +9 more | EDGAR |
| 2025-09-08 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Conversion (C): 1,758,907 @ $0 · Conversion (C): 10,949,014 @ $0 · Conversion (C): 994,899 @ $0 · Conversion (C): 2,573,745 @ $0 · Conversion (C): 1,758,907 (derivative) @ $0 · Conversion (C): 10,949,014 (derivative) @ $0 · +2 more | EDGAR |
| 2025-06-24 | 4 | Okta, Inc. (OKTA) | Option exercise (M): 2,832 @ $0 · Option exercise (M): 2,832 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Other (J): 4,803,998 @ $0 · Other (J): 21,898,032 @ $0 · Other (J): 1,989,800 @ $0 · Other (J): 2,639,238 @ $0 · Other (J): 3,995,652 @ $0 · Other (J): 363,661 @ $0 · +18 more | EDGAR |
| 2025-06-09 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Conversion (C): 4,803,998 @ $0 · Conversion (C): 21,898,032 @ $0 · Conversion (C): 1,989,800 @ $0 · Conversion (C): 2,639,238 @ $0 · Conversion (C): 4,803,998 (derivative) @ $0 · Conversion (C): 21,898,032 (derivative) @ $0 · +2 more | EDGAR |
| 2025-05-22 | 4 | Starco Brands, Inc. (STCB) jointly with Andreessen Horowitz Fund IV, L.P., AH Equity Partners IV, L.L.C., AH Parallel Fund IV, L.P., AH Equity Partners IV (Parallel), L.L.C., Andreessen Horowitz Fund III, L.P., AH Equity Partners III, L.L.C., a16z Seed-III, LLC, Andreessen Marc L | Other (J): 38,592,602 · Other (J): 7,433,138 · Other (J): 1,960,638 · Other (J): 100,607 | EDGAR |
| 2025-03-12 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Conversion (C): 219,698 @ $0 · Conversion (C): 73,233 @ $0 · Sale (S): 169,818 @ $34.06 · Sale (S): 56,606 @ $34.06 · Sale (S): 49,880 @ $34.62 · Sale (S): 16,627 @ $34.62 · +2 more | EDGAR |
| 2024-12-11 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Other (J): 2,401,999 @ $0 · Other (J): 10,949,016 @ $0 · Other (J): 994,901 @ $0 · Other (J): 866,961 @ $0 · Other (J): 36,129 @ $0 · Conversion (C): 76,251 @ $0 · +9 more | EDGAR |
| 2024-12-09 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Conversion (C): 2,401,999 @ $0 · Conversion (C): 10,949,016 @ $0 · Conversion (C): 994,901 @ $0 · Conversion (C): 2,401,999 (derivative) @ $0 · Conversion (C): 10,949,016 (derivative) @ $0 · Conversion (C): 994,901 (derivative) @ $0 | EDGAR |
| 2024-12-02 | 4 | Starco Brands, Inc. (STCB) jointly with Andreessen Horowitz Fund IV, L.P., AH Equity Partners IV, L.L.C., AH Parallel Fund IV, L.P., AH Equity Partners IV (Parallel), L.L.C., Andreessen Horowitz Fund III, L.P., AH Equity Partners III, L.L.C., a16z Seed-III, LLC, Andreessen Marc L | Other (J): 31,411,937 · Other (J): 6,502,936 · Other (J): 4,066,364 · Other (J): 88,016 | EDGAR |
| 2024-10-17 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with AH Equity Partners Bio I, L.L.C., AH Bio Fund I, L.P., AH Equity Partners Bio IV, L.L.C., AH Bio Fund IV, L.P., Andreessen Marc L | Conversion (C): 1,398,067 · Purchase (P): 181,818 @ $11 · Purchase (P): 545,454 @ $11 · Conversion (C): 15,001,312 (derivative) · Conversion (C): 679,163 (derivative) | EDGAR |
| 2024-09-12 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Other (J): 2,401,999 @ $0 · Other (J): 10,949,016 @ $0 · Other (J): 994,901 @ $0 · Other (J): 762,357 @ $0 · Other (J): 30,491 @ $0 · Sale (S): 9,604 @ $44.34 · +14 more | EDGAR |
| 2024-09-10 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Conversion (C): 2,401,999 @ $0 · Conversion (C): 10,949,016 @ $0 · Conversion (C): 994,901 @ $0 · Conversion (C): 2,401,999 (derivative) @ $0 · Conversion (C): 10,949,016 (derivative) @ $0 · Conversion (C): 994,901 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Okta, Inc. (OKTA) | Option exercise (M): 2,818 @ $0 · Option exercise (M): 2,818 (derivative) @ $0 · Grant/award (A): 2,832 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Samsara Inc. (IOT) jointly with Andreessen Horowitz LSV Fund I, L.P., Andreessen Horowitz LSV Fund I-B, L.P., Andreessen Horowitz LSV Fund I-Q, L.P., AH Equity Partners LSV I, L.L.C., Andreessen Horowitz Fund IV, L.P., Andreessen Horowitz Fund IV-A, L.P., Andreessen Horowitz Fund IV-B, L.P., Andreessen Horowitz Fund IV-Q, L.P., AH Equity Partners IV, L.L.C. | Conversion (C): 277,484 @ $0 · Sale (S): 265,276 @ $28.84 · Sale (S): 12,208 @ $29.72 · Conversion (C): 277,484 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1166586 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →